Automatic Data Processing Inc (ADP) Stock Price Today
Aura AI Summary
Key Stats
- $96.84BMARKET_CAP
- -VOLUME
- IndustrialsSECTOR
- $310.94FIFTY_TWO_WEEK_HIGH
- $188.79FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- $97.91BENTERPRISE_VALUE
- 2.81%DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track Automatic Data Processing Inc (ADP) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Automatic Data Processing Inc has traded between a low of $188.79 and a high of $310.94, highlighting its annual price range. Buy and sell Automatic Data Processing Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Automatic Data Processing Inc
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Most Recent News
Global Family Office Summit in Lake Como spotlights AI, private markets, and global investment trends.
The 32nd Global Family Office Investment Summit in Lake Como gathered over 200 family office leaders, investors, and entrepreneurs from 27 countries to discuss emerging trends in AI, private equity, healthcare innovation, and global investment opport...

GuideAI appoints vascular expert Dr. Benenati after FDA clears its AI vascular triage software VAOT
GuideAI Health Corp. has appointed Dr. James F. Benenati, a leading interventional radiologist, to its Advisory Board following FDA 510(k) clearance of its AI software, VascularAssist Occlusion Triage (VAOT). VAOT is designed to help radiologists pri...

VERAXA Biotech advances cancer therapy pipeline focusing on BiTAC technology and seeks partnerships.
VERAXA Biotech updated on its progress in developing novel cancer therapies using its proprietary BiTAC platform, focusing on conditionally active T cell engagers and bispecific antibody-drug conjugates. The company plans to prioritize investment in ...
